Arnold G Vulto (Arnold Vulto)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 17

Top Topics

Tyrosine Kinase

Positive Breast Cancer

Juvenile Idiopathic Arthritis

Health Insurance

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Pharmaceuticals (Basel, Switzerland)

Journal of pharmaceutical policy and practice

Applied health economics and health policy

This page only lists publications with an associated author ORCID identifier.

Publications

Yannick Vandenplas, Steven R A Simoens, Florian Turk, Arnold G Vulto, Isabelle Huys
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines. Applied health economics and health policy 20 (6) (2022)
Teresa Barcina Lacosta, Arnold G Vulto, Adina Turcu-Stiolica, Isabelle Huys, Steven R A Simoens
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 36 (2) (2022)
Erik H P van Putten, Anne Kleijn, Victor W van Beusechem, David Noske, Cor H J Lamers, Anna L de Goede, Sander Idema, Daphna Hoefnagel, Jenneke J Kloezeman, Juan Fueyo, Frederick F Lang, Charlotte E Teunissen, René M Vernhout, Cathy Bakker, Winald R Gerritsen, David T Curiel, Arnold G Vulto, Martine L M Lamfers, Clemens M F Dirven
Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (8) (2022)
Evelien Moorkens, Arnold G Vulto, Isabelle Huys
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? mAbs 12 (1) (2021)
Paul Cornes, Pere Gascon, Arnold G Vulto, Matti Aapro
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (3) (2021)
Steven Simoens, Arnold G Vulto
A health economic guide to market access of biosimilars. Expert opinion on biological therapy 21 (1) (2021)
Liese Barbier, Steven R A Simoens, Arnold G Vulto, Isabelle Huys
European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (6) (2021)
Liese Barbier, Steven R A Simoens, Caroline Soontjens, Barbara Claus, Arnold G Vulto, Isabelle Huys
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices. Pharmaceuticals (Basel, Switzerland) 14 (6) (2021)
Binita Dutta, Isabelle Huys, Arnold G Vulto, Steven R A Simoens
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (2) (2021)
Liese Barbier, Steven R A Simoens, Arnold G Vulto, Isabelle Huys
European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (6) (2021)
Evelien Moorkens, Arnold G Vulto, James Kent, Lindsay McClure, Richard Boldero, Thibault Vanhove, Steven R A Simoens, Isabelle Huys
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 35 (1) (2021)
Yannick Vandenplas, Steven R A Simoens, Philippe Van Wilder, Arnold G Vulto, Isabelle Huys
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals (Basel, Switzerland) 14 (2) (2021)
Steven R A Simoens, Arnold G Vulto, Pieter Dylst
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. Pharmaceuticals (Basel, Switzerland) 14 (5) (2021)
Liese Barbier, Yannick Vandenplas, Steven R A Simoens, Paul J Declerck, Arnold G Vulto, Isabelle Huys
Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. Journal of pharmaceutical policy and practice 14 (1) (2021)
Evelien Moorkens, Teresa Barcina Lacosta, Arnold G Vulto, Martin Schulz, Gabriele Gradl, Salka Enners, Gisbert W Selke, Isabelle Huys, Steven R A Simoens
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals (Basel, Switzerland) 13 (10) (2020)
Evelien Moorkens, Arnold G Vulto, Isabelle Huys
Biosimilars in Belgium: a proposal for a more competitive market. Acta clinica Belgica 76 (6) (2020)
Arnold G Vulto, Jackie Vanderpuye-Orgle, Martin van der Graaff, Steven R A Simoens, Lorenzo Dagna, Richard Macaulay, Beenish Majeed, Jeffrey Lemay, Jane Hippenmeyer, Sebastian Gonzalez-McQuire
Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review. Pharmaceuticals (Basel, Switzerland) 13 (11) (2020)